Filter By:
Viewing 1 to 8 (8 Total)

ARRY-380

06/01/2015

American Society of Clinical Oncology Meeting

ONT-380 in the Treatment of HER2+ Breast Cancer Central Nervous System (CNS) Metastases (Mets)

C. Ferrario, et al.

ARRY-380

10/17/2012

American Association of Pharmaceutical Scientists, Annual Meeting and Exposition

Amorphous Dispersion Development of ARRY-380, an ErbB2 Selective Inhibitor

C. Lindemann, et al.

ARRY-380

10/17/2012

American Association of Pharmaceutical Scientists, Annual Meeting and Exposition

Solid-State Characterization of Seven Isomorphic Solvates of ARRY-380

C. Lindemann, et al.

ARRY-380

04/01/2012

American Association for Cancer Research Annual Meeting

ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice

V. Dinkel, et al.

ARRY-380

11/14/2011

AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics

ARRY-380, a Selective HER2 Inhibitor: From Drug Design to Clinical Evaluation

S. L. Moulder, et al.

ARRY-380

04/03/2011

American Association for Cancer Research Annual Meeting

ARRY-380: A Selective, Oral HER2 Inhibitor for the Treatment of Solid Tumors

K. Koch Ph.D.

ARRY-380

12/10/2010

San Antonio Breast Cancer Symposium

Data from a Completed Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2

S. L. Moulder, et al.

ARRY-380

10/01/2010

American Society of Clinical Oncolog Breast Cancer Symposium

A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2

PK Morrow, et al.